Zobrazeno 1 - 10
of 1 447
pro vyhledávání: '"G. J. de Jong"'
Autor:
Luis Puig, Antonio Costanzo, Elke M. G. J. de Jong, Tiago Torres, Richard B. Warren, Robert Wapenaar, Sven Wegner, Patricia Gorecki, Talia Gramiccia, Maria Jazra, Jozefien Buyze, Curdin Conrad
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2539-2558 (2024)
Abstract Introduction The interleukin-23p19 subunit inhibitor, guselkumab, has demonstrated improvements in clinical and patient-reported outcome (PRO) measures in patients with moderate-to-severe psoriasis. Understanding the relationship among clini
Externí odkaz:
https://doaj.org/article/ab526a4a99574512a77a238ef4a81a03
Autor:
C. D. Wortman, L. T. H. Godding, Q. Yin, K. V. Kwee, M. B. Visch, E. M. G. J. de Jong, J. M. P. A. van den Reek, M. Tjioe
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Background During the COVID-19 pandemic, psoriasis care underwent significant changes in consultation methods and treatment management. However, comprehensive data on these changes and patient perceptions are limited.Aims To evaluate the pandemic’s
Externí odkaz:
https://doaj.org/article/455c52ee7de348c1899d8a83dfa80028
Autor:
Thom S. Lysen, Edmée J. G. M. Crombag, Loek Lennaerts, Amr Makady, Ralph H. Bruin, Kelly Mulder, Elke M. G. J. de Jong, Hanne van Ballegooijen
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractBackground Psoriasis is a prevalent, chronic skin disease with a potential impact on work productivity, medical consumption costs, and quality of life. The influence of the extent of skin lesions on these outcomes is not well known.Objective
Externí odkaz:
https://doaj.org/article/61add975717347399ade39c5223722e4
Autor:
Tamara W. van Hal, Juul M. P. A. van den Reek, Mark H. Wenink, Marisol E. Otero, Paul M. Ossenkoppele, Marcellus D. Njoo, Annet Oostveen, Bas Peters, Milan Tjioe, Else N. Kop, John E. M. Körver, Sharon R. P. Dodemont, Marloes M. Kleinpenning, Maartje A. M. Berends, Wendelien R. Veldkamp, Martijn B. A. van Doorn, Johannes M. Mommers, Robert-Jan Lindhout, Astrid L. A. Kuijpers, Paula P. van Lümig, C. (Els) J. de Jonge, Ron A. Tupker, Judith Hendricksen, Romy R. Keijsers, Frank H. J. van den Hoogen, Johanna E. Vriezekolk, Elke M. G. J. de Jong
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractBackground: Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this
Externí odkaz:
https://doaj.org/article/a0ecbd2dbd2848a58e15cb47119ba98d
Autor:
C. A. M. van Riel, C. A. J. Michielsens, M. E. van Muijen, L. S. van der Schoot, J. M. P. A. van den Reek, E. M. G. J. de Jong
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors (i) and interleukin (IL)-12/23i) has been described in a previous scoping review. The literature on the DR of the newest generation of biologics (IL-17/23i)
Externí odkaz:
https://doaj.org/article/d96b176483684acb84df09af3da5c14a
Autor:
Kevin V. Kwee, Jean-Luc Murk, Qiqi Yin, M. Birgitte Visch, Linda Davidson, Elke M. G. J. de Jong, Juul M. P. A. van den Reek, Milan Tjioe
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is still limited. Objectives (1) to estimate the prevalence of SARS-CoV-2 infection
Externí odkaz:
https://doaj.org/article/5bbb433f11f24b4ebee8812a7667dde9
Autor:
Elke L. M. ter Haar, Juul M. P. A. van den Reek, Kristian Gaarn Du Jardin, Almudena Barbero-Castillo, Elke M. G. J. de Jong, Satish F. K. Lubeek
Publikováno v:
Acta Dermato-Venereologica, Vol 103 (2023)
The evidence on treating older patients with psoriasis with modern biologics is scarce. This study compared the efficacy and safety of tildrakizumab among younger and older patients with psoriasis (
Externí odkaz:
https://doaj.org/article/c8c47d9828354437a429231c9fef21e9
Autor:
Elke L. M. ter Haar, Marcia Tummers, Ewald M. Bronkhorst, Peter C. M. van de Kerkhof, Elke M. G. J. de Jong, Satish F. K. Lubeek
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 7, Pp 2983-2990 (2022)
Background Evidence-based guidance in older adults (≥65 years) with psoriasis is sparse and undertreatment might be present. Objectives To assess prescribing patterns, comfort levels, barriers and needs of dermatologists when treating older adults
Externí odkaz:
https://doaj.org/article/a08dbd3cf5b54da49f48b98b21b151ad
Autor:
Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 5, Pp 2680-2684 (2022)
Background Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent overtreatment, and lower risks and costs. However, fear for increased anti-drug a
Externí odkaz:
https://doaj.org/article/536a53e9789542ddb193b8939be0e2cc
Autor:
Mirjam J. Schaap, Susanne C. E. Broekhuis, Saskia Spillekom-van Koulil, Hans M. M. Groenewoud, Elke M. G. J. de Jong, Marieke M. B. Seyger
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 5, Pp 2527-2533 (2022)
Background Treatment needs of young psoriasis patients and parents are not widely studied and could advance patient-centered care. Objective To explore treatment goals and preferences of pediatric psoriasis patients, young adults, and parents. Method
Externí odkaz:
https://doaj.org/article/90f0c2df10f54e59a08b3b036ad55618